Annals of Surgical Oncology

, Volume 25, Supplement 3, pp 683–684 | Cite as

ASO Author Reflections: Predicting High-Risk Oncotype DX Recurrence Scores as a Strategy for Assessing Neoadjuvant Chemotherapy Eligibility

  • Lisa NewmanEmail author
ASO Author Reflections



There are no conflicts of interest.


  1. 1.
    Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164–72.CrossRefGoogle Scholar
  2. 2.
    Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379:111–21.CrossRefGoogle Scholar
  3. 3.
    Sparano JA, Gray RJ, Makower DF, et al. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med. 2015;373:2005–14.CrossRefGoogle Scholar
  4. 4.
    Park KU, Chen Y, Chitale D, et al. Utilization of the 21-gene recurrence score in a diverse breast cancer patient population: development of a clinicopathologic model to predict high-risk scores and response to neoadjuvant chemotherapy. Ann Surg Oncol. 2018;25:1921–7.CrossRefGoogle Scholar
  5. 5.
    Farrugia DJ, Landmann A, Zhu L, et al. Magee equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor-positive, HER2-negative/equivocal breast tumors. Mod Pathol. 2017;30:1078–85.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  1. 1.Department of SurgeryWeill Cornell MedicineNew YorkUSA

Personalised recommendations